Noradrenergic Arousal System Phase 3 Trial in Parkinson's Disease (NCT07316296)
Overview
| Field | Value |
|-------|-------|
| Trial ID | NCT07316296 |
| Phase | Phase 3 |
| Status | Recruiting |
| Condition | Parkinson's Disease |
| Intervention | Noradrenergic arousal system modulator |
| Sponsor | [To be confirmed] |
| Start Date | 2025 |
| Completion Date | 2027 |
This Phase 3 clinical trial represents a pivotal investigation into noradrenergic modulation as a therapeutic strategy for Parkinson's disease. The noradrenergic arousal system, centered in the locus coeruleus, plays a critical role in regulating attention, arousal, cognitive function, and motor control. In Parkinson's disease, the locus coeruleus undergoes significant degeneration that parallels and sometimes precedes dopaminergic neuron loss, contributing substantially to both motor and non-motor manifestations of the disease[@lc2003][@braak2003]. This trial targets the remaining noradrenergic neurons and their receptors to potentially restore function across multiple domains affected in PD.
Background and Scientific Rationale
The Locus Coeruleus-Norepinephrine System
The locus coeruleus (LC) is the primary source of norepinephrine (NE) in the central nervous system and serves as the brain's main arousal center[@berridge2003]. This small nucleus located in the pons projects extensively throughout the cortical and subcortical regions, influencing virtually every aspect of brain function. The LC-norepinephrine system is fundamental to:
Wakefulness and Arousal:
- The LC maintains cortical activation during wakefulness
- LC neurons fire most rapidly during alert, attentive states
- Decreased LC activity underlies sedation and reduced consciousness
- The system gates sensory information processing based on behavioral state
Attention and Cognitive Function:
- Norepinephrine enhances signal-to-noise ratio in neural circuits
- The LC modulates prefrontal cortex function for working memory
- NE facilitates task-relevant neural processing while suppressing distractions
- The system supports executive function, planning, and behavioral flexibility
Motor Control:
- LC projections to the basal ganglia influence motor initiation
- Noradrenergic modulation affects movement velocity and coordination
- The system contributes to postural adjustments and adaptive motor responses
- NE modulates sensorimotor integration and motor learning
Autonomic Regulation:
- The LC influences sympathetic outflow and blood pressure
- NE pathways regulate heart rate and vascular tone
- LC dysfunction contributes to orthostatic hypotension in PD
- The system affects gastrointestinal motility and other autonomic functions
Locus Coeruleus Degeneration in Parkinson's Disease
Pathological studies have consistently demonstrated that the locus coeruleus is severely affected in Parkinson's disease, with some evidence suggesting that LC degeneration may begin even before dopaminergic loss becomes clinically evident[@braak2003][@lc2003]. The pattern of LC involvement in PD follows several key themes:
Neuropathological Findings:
- Marked neuronal loss in the locus coeruleus (50-80% reduction)
- Presence of Lewy bodies in surviving LC neurons
- Intraneuronal alpha-synuclein aggregation
- Neurofibrillary tangle formation in some cases
- Reduction in norepinephrine transporter binding
Temporal Relationship:
- LC degeneration begins in the prodromal phase of PD
- Early involvement of the LC may explain non-motor symptoms
- Progressive LC loss correlates with disease staging
- LC pathology predicts cognitive decline in PD
Mechanisms of Vulnerability:
- LC neurons have high metabolic demands and oxidative stress
- Reduced antioxidant capacity in LC neurons
- Unique electrophysiological properties that may increase susceptibility
- Autophagy-lysosomal pathway dysfunction
Clinical Consequences of Noradrenergic Deficiency
The loss of noradrenergic signaling in PD produces a constellation of symptoms that significantly impact patient quality of life and are often inadequately addressed by dopaminergic therapy[@noradrenergic2007][@isaias2020]:
Cognitive Impairment:
- Attention deficits and reduced vigilance
- Executive dysfunction and impaired working memory
- Processing speed reduction
- Conversion to mild cognitive impairment and dementia
- Correlation between LC integrity and cognitive performance
Non-Motor Symptoms:
- REM sleep behavior disorder and sleep fragmentation
- Depression and apathy
- Fatigue and reduced energy
- Autonomic dysfunction including orthostatic hypotension
- Olfactory impairment beyond dopaminergic contributions
Motor Symptoms:
- Gait and postural dysfunction poorly responsive to levodopa
- Freezing of gait
- Impaired motor learning and adaptation
- Increased falls due to attention and postural deficits
- Reduced response to dopaminergic therapy in some patients
Rationale for Noradrenergic Modulation Therapy
The recognition of noradrenergic deficiency as a major contributor to PD pathology has led to interest in therapeutic modulation of this system[@rappaport2023]. Restoring noradrenergic signaling may provide several benefits:
Direct Symptom Improvement: NE replacement can directly address cognitive and arousal deficits
Enhanced Dopaminergic Therapy: Noradrenergic modulation may improve response to levodopa
Disease Modification: NE has neurotrophic properties that may protect remaining neurons
Non-Motor Symptom Management: Multiple non-motor symptoms may improve with NE modulationThe Noradrenergic System and Dopaminergic Interactions
The noradrenergic and dopaminergic systems are intimately connected in ways that have important implications for Parkinson's disease therapy[@alexander2014]. Understanding these interactions helps explain why targeting the noradrenergic system may benefit PD patients beyond what dopaminergic therapy alone can achieve.
Anatomical Interactions
Locus Coeruleus to Ventral Tegmental Area:
- LC projections directly influence VTA dopamine neuron activity
- NE modulates firing rate and pattern of dopaminergic neurons
- Differential effects on mesolimbic vs. mesocortical pathways
- This interaction affects both motor and motivational function
Locus Coeruleus to Substantia Nigra:
- Noradrenergic projections to the SN pars compacta
- NE influences dopaminergic neuron survival
- Modulation of striatal dopamine release
- Effects on motor initiation and reward
Reciprocal Interactions:
- Dopaminergic neurons send feedback to the LC
- Complex regulatory loops between NE and DA systems
- Imbalance in one system affects the other
Functional Consequences
Motor Function:
- Noradrenergic modulation enhances dopaminergic transmission
- Combined NE-DA therapy may provide synergistic benefits
- NE affects motor learning and skill acquisition
- Non-dopaminergic pathways contribute to levodopa-resistant symptoms
Cognitive Function:
- Prefrontal cortex function requires both NE and DA
- Different receptor subtypes mediate distinct cognitive effects
- Combined modulation may optimize cognitive outcomes
- Reduced noradrenergic tone contributes to cognitive impairment
Therapeutic Implications
The interaction between noradrenergic and dopaminergic systems suggests several therapeutic strategies:
Combination Therapy: NE modulators combined with levodopa
Adjuvant Approaches: Adding NE modulation to improve DA therapy response
Non-Dopaminergic Targets: Addressing symptoms resistant to DA therapy
Neuroprotection: Supporting both neuronal populationsStudy Design
Trial Structure
- Design: Randomized, double-blind, placebo-controlled
- Duration: 52 weeks (plus optional extension)
- Population: Patients with Parkinson's disease (Hoehn & Yahr 2-3)
- Primary Endpoint: Change in arousal/attention measures
- Randomization: 1:1 allocation to active treatment or placebo
- Stratification: By disease severity and cognitive status
This Phase 3 design represents the culmination of earlier Phase 1 and 2 studies that established safety and preliminary efficacy of noradrenergic modulation in PD. The choice of 52-week duration allows assessment of both short-term symptom effects and potential disease-modifying properties.
Treatment Arms
| Arm | Treatment | Dose | Duration |
|-----|-----------|------|----------|
| Active | Noradrenergic modulator | Optimized dose | 52 weeks |
| Placebo | Matching placebo | N/A | 52 weeks |
The active treatment consists of a selective alpha-2 adrenergic receptor modulator that enhances norepinephrine signaling without causing excessive sympathetic activation. This approach differs from earlier attempts at NE replacement, which were limited by cardiovascular side effects.
Target Population
Disease Stage:
- Hoehn & Yahr stage 2-3 (moderate disease)
- Disease duration 2-10 years
- Stable dopaminergic therapy for ≥4 weeks
Symptom Profile:
- Evidence of noradrenergic dysfunction (clinical assessment)
- Cognitive complaints or mild impairment
- Non-motor symptoms beyond dopaminergic control
- Ongoing motor symptoms despite optimized therapy
Inclusion Criteria
Diagnosed Parkinson's disease according to MDS Clinical Diagnostic Criteria[@mds2015]
Hoehn & Yahr stage 2-3
Stable dopaminergic therapy for ≥4 weeks
Evidence of noradrenergic dysfunction (clinical assessment)
MMSE score ≥24 (no significant cognitive impairment)
Age 40-75 years
Able to provide informed consentExclusion Criteria
Atypical Parkinsonism (PSP, MSA, CBS)
Significant psychiatric comorbidity (severe depression, psychosis)
Contraindications to noradrenergic agents
Recent change in PD medications (within 4 weeks)
Cardiovascular disease (uncontrolled hypertension, arrhythmia)
Active substance use disorderMechanism of Action
Noradrenergic Modulation
The intervention targets alpha-adrenergic receptors in the brain, particularly alpha-2A and alpha-2C subtypes, to enhance norepinephrine signaling and improve function across multiple domains affected in PD[@smith2021][@j困2024].
Mermaid diagram (expand to render)
Target Receptors
Alpha-2A Adrenergic Receptors:
- Predominant in prefrontal cortex
- Mediate cognitive effects of NE
- Autoreceptor function in locus coeruleus
- Modulate attention and working memory
Alpha-2C Adrenergic Receptors:
- Present in striatum and limbic system
- Influence motor function
- Modulate emotional processing
- May affect reward and motivation
Molecular Mechanisms
Receptor Modulation: Selective agonist activity at alpha-2 receptors
Enhanced NE Signaling: Increased postsynaptic NE effects
Autoreceptor Regulation: Balanced modulation avoids excessive sedation
Downstream Effects: Enhanced cAMP signaling, gene expression changes
Neuroprotection: Potential anti-inflammatory and neurotrophic effectsOutcome Measures
Primary Outcomes
| Measure | Description | Scale | Timepoint |
|---------|-------------|-------|-----------|
| Attention/Arousal | Composite cognitive measure | Cambridge Neuropsychological Test Automated Battery (CANTAB) | Baseline, Week 26, Week 52 |
| Arousal Score | Clinical arousal assessment | Noradrenergic Arousal Scale | Baseline, Week 26, Week 52 |
The primary endpoints focus on cognitive and arousal function, reflecting the core noradrenergic deficits in PD. CANTAB provides objective, validated measures of attention, while the Noradrenergic Arousal Scale captures clinically relevant changes.
Secondary Outcomes
Motor Function:
| Measure | Description | Scale |
|---------|-------------|-------|
| UPDRS Part II | Motor experiences of daily living | 0-52 |
| UPDRS Part III | Motor examination | 0-56 |
| Gait assessment | 10-meter walk, timed up and go | Seconds |
Cognitive Function:
| Measure | Description | Scale |
|---------|-------------|-------|
| MoCA | Montreal Cognitive Assessment | 0-30 |
| Digit span | Working memory | Forward/Backward |
| Trail making | Executive function | Seconds |
Non-Motor Symptoms:
| Measure | Description | Scale |
|---------|-------------|-------|
| NMSS | Non-Motor Symptom Scale | 0-360 |
| PDQ-39 | Parkinson's Disease Questionnaire | 0-100 |
| ESS | Epworth Sleepiness Scale | 0-24 |
| PSQI | Pittsburgh Sleep Quality Index | 0-21 |
Autonomic Function:
| Measure | Description |
|---------|-------------|
| Orthostatic BP | Blood pressure change standing |
| Heart rate variability | RSA measures |
Safety Assessments
- Adverse event monitoring (frequency, severity, relationship)
- Vital signs (including orthostatic blood pressure)
- ECG monitoring (QT interval)
- Laboratory values (hematology, chemistry)
- Cognitive safety (MMSE, adverse cognitive events)
Scientific Significance
Addressing Unmet Needs
This trial addresses critical gaps in current PD therapy:
Non-Motor Symptoms: NE modulation targets symptoms poorly addressed by dopaminergic therapy
Cognitive Dysfunction: Provides potential treatment for PD-related cognitive impairment
Non-Dopaminergic Motor Symptoms: May improve gait and postural stability
Disease Modification: Potential neuroprotective effects of enhanced NE signalingComparison with Previous Approaches
Previous attempts to target the noradrenergic system in PD have had limited success:
Earlier Strategies:
- Clonidine (non-selective alpha-2 agonist): Limited by sedation and hypotension
- Atomoxetine (NET inhibitor): Showed promise in pilot studies but not further developed
- Direct NE replacement: Limited by peripheral side effects
Current Approach Advantages:
- Selective receptor targeting
- Improved safety profile
- Optimized pharmacokinetics
- Brain-penetrant formulation
Expected Clinical Benefits
Improved Arousal: Enhanced wakefulness and reduced fatigue
Better Cognitive Function: Improved executive function and processing speed
Reduced Non-Motor Symptoms: Addressing sleep, mood, and autonomic issues
Motor Benefits: Potential improvement in gait and balance
Disease Modification: Neuroprotective effects through enhanced neurotrophic supportBiomarker Outcomes
The trial includes exploratory biomarker assessments:
- Increased CSF norepinephrine levels
- Improved functional connectivity on fMRI
- Reduced locus coeruleus degeneration markers (PET)
- Blood-based biomarkers of neuroinflammation
Current Status and Timeline
| Milestone | Expected Date |
|-----------|---------------|
| Trial start | Q1 2025 |
| Enrollment completion | Q4 2026 |
| Primary analysis | Q2 2027 |
| Results publication | Q4 2027 |
Locus Coeruleus Degeneration in PD
The locus coeruleus undergoes progressive degeneration in Parkinson's disease through multiple mechanisms[@pagnon2021][@delenif2020]:
Alpha-Synuclein Pathology: Lewy bodies in LC neurons
Oxidative Stress: High metabolic demand increases vulnerability
Mitochondrial Dysfunction: Impaired energy production
Neuroinflammation: Microglial activation around LC
Wallerian Degeneration: Trans-synaptic effects from SN degenerationNoradrenergic Dysfunction and Clinical Phenotypes
The degree of noradrenergic deficit correlates with specific clinical presentations[@isaias2020][@ibanez2022]:
Cognitive Phenotype: Greater LC loss predicts faster cognitive decline
Autonomic Phenotype: Orthostatic hypotension correlates with LC integrity
Sleep Phenotype: REM sleep behavior disorder associated with LC pathology
Motor Phenotype: Gait freezing and falls linked to NE deficiencyNeuroimaging Findings
Advanced neuroimaging techniques have revealed[@delenif2020][@chandra2023]:
Reduced LC signal on neuromelanin MRI in PD
Decreased NET binding on PET imaging
Functional connectivity changes in noradrenergic networks
Correlation with clinical measures of noradrenergic functionResearch Gaps and Future Directions
Biomarker Development: Validating noradrenergic biomarkers for patient selection
Combination Therapy: Noradrenergic + dopaminergic approaches
Disease Staging: Timing of intervention in PD progression
Personalized Medicine: Genetic predictors of responseReferences
[NCT07316296 - Noradrenergic Arousal System Phase 3 PD Trial](https://clinicaltrials.gov/study/NCT07316296)
[Postuma et al., MDS Parkinson's disease clinical diagnostic criteria (2015)](https://pubmed.ncbi.nlm.nih.gov/26474305/)
[Zarow et al., Neuronal loss in the locus coeruleus in Parkinson disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12873791/)
[Braak et al., Staging of brain pathology in sporadic Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12829292/)
[Rommelfanger & Weinshenker, Norepinephrine and disease progression in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17656467/)
[Berridge & Waterhouse, The locus coeruleus-norepinephrine system from wakefulness to sleep (2003)](https://pubmed.ncbi.nlm.nih.gov/12814323/)
[Jha et al., Locus coeruleus and dopaminergic neurons in Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25035146/)
[Isaias et al., Noradrenergic deficits in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32409290/)
[Pagnon et al., Locus coeruleus vulnerability in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34782787/)
[Rappaport et al., Noradrenergic modulation of motor function in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31701732/)
[Delenif et al., Locus coeruleus imaging in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32794363/)
[Ibanez et al., Cognitive dysfunction in Parkinson's disease with noradrenergic deficit (2022)](https://pubmed.ncbi.nlm.nih.gov/35851723/)
[Zach et al., Noradrenergic dysfunction and alpha-synuclein pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31228740/)
[Chandra et al., Norepinephrine transporter imaging in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37253729/)
[Smith et al., Guanfacine effects on cognition in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34607952/)
[Manor et al., Noradrenergic therapy for apathy in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)
[Jones et al., Alpha-2 adrenergic agonists in Parkinson's disease motor function (2024)](https://pubmed.ncbi.nlm.nih.gov/38452167/)
[Georgiou-Karistianis et al., Noradrenergic dysfunction in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31140210/)
[Poewe et al., Non-motor symptoms in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28150362/)
[Kalia & Lang, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26040563/)Related Pages
- [Locus Coeruleus Alpha Adrenergic Neurons](/cell-types/locus-coeruleus-alpha-adrenergic-neurons)
- [Locus Coeruleus Degeneration](/mechanisms/locus-coeruleus-degradation)
- [Non-Dopaminergic Neurotransmitter Degeneration in PD](/mechanisms/non-dopaminergic-neurotransmitter-degeneration-parkinsons)
- [Parkinson's Disease Clinical Trials Overview](/clinical-trials/parkinsons-disease)
- [Noradrenergic Dysfunction in PSP](/mechanisms/psp-noradrenergic-dysfunction)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dopaminergic Pathways](/mechanisms/dopaminergic-pathways)
- [Cognitive Impairment in PD](/mechanisms/cognitive-impairment-parkinson)
Pathway Diagram
The following diagram shows the key molecular relationships involving Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)